A Phase I/II, Multi-center Clinical Study: Dose-finding Phase I Study of Foritinib Succinate in Advanced ALK-positive NSCLC Patients and Phase II Study of Foritinib Succinate in ALK or ROS1-positive NSCLC Patients
Latest Information Update: 12 Dec 2023
At a glance
- Drugs Foritinib succinate (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Shanghai Fosun Pharmaceutical
Most Recent Events
- 24 Oct 2023 Results (n=143; data cutoff date: 13 Dec 2021) of a circulating tumor DNA (ctDNA) biomarker analysis of patients with advanced, ALK-rearranged NSCLC ; using tumor tissue samples from phase 2a portion of this study presented at the 48th European Society for Medical Oncology Congress
- 07 Jun 2022 Results (At a clinical cutoff date of January 18, 2022, n=45 )of updated phase 1 results and preliminary phase 2 data, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jul 2021 Planned End Date changed from 17 Jun 2023 to 31 Mar 2026.